AU2016228751B2 - Rp2 vectors for treating x-linked retinitis pigmentosa - Google Patents

Rp2 vectors for treating x-linked retinitis pigmentosa Download PDF

Info

Publication number
AU2016228751B2
AU2016228751B2 AU2016228751A AU2016228751A AU2016228751B2 AU 2016228751 B2 AU2016228751 B2 AU 2016228751B2 AU 2016228751 A AU2016228751 A AU 2016228751A AU 2016228751 A AU2016228751 A AU 2016228751A AU 2016228751 B2 AU2016228751 B2 AU 2016228751B2
Authority
AU
Australia
Prior art keywords
vector
mammal
retina
rpgr
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228751A
Other languages
English (en)
Other versions
AU2016228751A1 (en
Inventor
Suja HIRIYANNA
Suddhasil MOOKHERJEE
Anand Swaroop
Zhijian Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2016228751A1 publication Critical patent/AU2016228751A1/en
Application granted granted Critical
Publication of AU2016228751B2 publication Critical patent/AU2016228751B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2016228751A 2015-03-11 2016-03-11 Rp2 vectors for treating x-linked retinitis pigmentosa Active AU2016228751B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131661P 2015-03-11 2015-03-11
US62/131,661 2015-03-11
PCT/US2016/022072 WO2016145345A1 (en) 2015-03-11 2016-03-11 Rp2 and rpgr vectors for treating x-linked retinitis pigmentosa

Publications (2)

Publication Number Publication Date
AU2016228751A1 AU2016228751A1 (en) 2017-09-21
AU2016228751B2 true AU2016228751B2 (en) 2022-01-13

Family

ID=56879752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016228751A Active AU2016228751B2 (en) 2015-03-11 2016-03-11 Rp2 vectors for treating x-linked retinitis pigmentosa

Country Status (6)

Country Link
US (2) US10646588B2 (https=)
EP (2) EP3268481B1 (https=)
JP (2) JP6935049B2 (https=)
AU (1) AU2016228751B2 (https=)
CA (1) CA2979229A1 (https=)
WO (1) WO2016145345A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268481B1 (en) 2015-03-11 2020-05-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Rpgr vectors for treating x-linked retinitis pigmentosa
KR102704296B1 (ko) * 2017-11-15 2024-09-05 더 리젠츠 오브 더 유니버시티 오브 미시간 Rdh12 암호화 영역을 포함하는 바이러스 벡터 및 망막 이영양증을 치료하는 방법
US20210348193A1 (en) * 2018-09-21 2021-11-11 Nightstarx Limited Compositions and methods for treating retinitis pigmentosa
CA3131023A1 (en) * 2019-02-22 2020-08-27 Michael R. Volkert Oxr1 gene therapy
CN115279902A (zh) * 2019-08-30 2022-11-01 贝勒医学院 用于调控基因表达的系统
WO2021178668A1 (en) * 2020-03-04 2021-09-10 University Of Massachusetts Compositions and methods for modulating rpgr expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011210A1 (en) * 2012-07-11 2014-01-16 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
ES2751999T3 (es) 2008-01-29 2020-04-02 Applied Genetic Tech Corporation Producción recombinante de virus adeno-asociados usando células BHK en suspensión
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
EP2714709B1 (en) * 2011-05-26 2018-04-18 University of Washington Compositions for use in cell and gene based methods to improve cardiac function
WO2014127196A1 (en) * 2013-02-15 2014-08-21 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Aav8 retinoschisin expression vector for treating x-linked retinoschisis
EP2970972B1 (en) * 2013-03-11 2018-08-15 Fondazione Telethon Mir-204 and mir-211 and uses thereof
US9534225B2 (en) * 2014-04-15 2017-01-03 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (RPGR)
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
GB201412011D0 (en) 2014-07-04 2014-08-20 Ucl Business Plc Treatments
HUE068183T2 (hu) * 2014-07-24 2024-12-28 Massachusetts Eye & Ear Infirmary RPGR génterápia a retinitis pigmentosa terápiájára
SI3265571T1 (sl) * 2015-03-03 2022-10-28 Fondazione Telethon Več vektorski sistem in njegove uporabe
EP3268481B1 (en) * 2015-03-11 2020-05-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Rpgr vectors for treating x-linked retinitis pigmentosa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011210A1 (en) * 2012-07-11 2014-01-16 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Late Breaking Abstracts: Presented at the American Society of Gene & Cell Therapy’s 16thAnnual Meeting, May 15–18, 2013, Salt Lake City, Utah", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 21, no. 9, 6 September 2013 (2013-09-06), US , pages e1 - e46, XP055258076, ISSN: 1525-0016, DOI: 10.1038/mt.2013.140 *
LEWIN, A. et al., "AAV-mediated gene therapy in animal models of autosomal dominant and X-linked retinitis pigmentosa", Molecular Syndromology, (2011), vol. 2, no. 6, page 265 *
N/A: "Abstracts of 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), ", MOLECULAR THERAPY, ELSEVIER INC., US, vol. 22, no. Suppl.1., 1 June 2014 (2014-06-01), US , pages S1 - S306, XP055310541, ISSN: 1525-0016, DOI: 10.1038/mt.2014.64 *
SUDDHASIL MOOKHERJEE ET AL: "A Low Dose AAV Vector Administration Preserves Cone Function in an Rp2 Knockout Mouse Model for Retinitis Pigmentosa", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, no. 13, 1 January 2014 (2014-01-01), XP055310549 *
W. A. BELTRAN, A. V. CIDECIYAN, A. S. LEWIN, S. IWABE, H. KHANNA, A. SUMAROKA, V. A. CHIODO, D. S. FAJARDO, A. J. ROMAN, W.-T. DEN: "Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 6, 7 February 2012 (2012-02-07), pages 2132 - 2137, XP055155762, ISSN: 00278424, DOI: 10.1073/pnas.1118847109 *
ZHIJIAN WU ET AL: "Preclinical Development of AAV Vectors for the Treatment of X-linked Retinitis Pigmentosa Caused by RPGR Mutations ", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, no. 13, 1 January 2014 (2014-01-01), pages 3305, XP055310512 *

Also Published As

Publication number Publication date
WO2016145345A1 (en) 2016-09-15
EP3268481B1 (en) 2020-05-27
EP3268481A1 (en) 2018-01-17
CA2979229A1 (en) 2016-09-15
EP3268481A4 (en) 2018-03-21
US20200289670A1 (en) 2020-09-17
EP3719134A1 (en) 2020-10-07
US20180043035A1 (en) 2018-02-15
JP6935049B2 (ja) 2021-09-15
JP2018509154A (ja) 2018-04-05
US11617801B2 (en) 2023-04-04
US10646588B2 (en) 2020-05-12
JP2021019611A (ja) 2021-02-18
EP3719134B1 (en) 2023-08-23
AU2016228751A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
US11617801B2 (en) RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
US20250243509A1 (en) Methods for treating eye disease
Komáromy et al. Gene therapy rescues cone function in congenital achromatopsia
AU2013287281B2 (en) AAV-mediated gene therapy for RPGR x-linked retinal degeneration
JP6827320B2 (ja) ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法
JP7170656B2 (ja) Ｍｅｃｐ２ベースの治療
JP6449175B2 (ja) 眼の遺伝子関連疾患の治療のための方法及び組成物
ES3061210T3 (en) Gene therapy for ocular disorders
JP7766393B2 (ja) 眼疾患のための遺伝子療法
US20240218394A1 (en) Gene therapy for ocular disorders
KR20180072713A (ko) 클로라이드 채널의 표적된 발현 및 이의 사용 방법
JP2021510301A (ja) 網膜障害を治療するための組成物及び方法
WO2020016425A1 (en) Compositions for the treatment of sarcopenia or disuse atrophy
US20240124893A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
ES2901613T3 (es) Lebecetina, una lectina de tipo C, como inhibidor de la neovascularización

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)